249 studies · 61 compounds
Peptide research, one study at a time
Each page tells one published paper in plain words: what they tested, how, what they found with the paper’s own numbers, and what it doesn’t show. Every number is checked against the paper, and the paper is linked.
Checked November 2026
By compound
By kind
Healing & recovery
BPC-157
- BPC-157: 10 of 12 women reported full interstitial cystitis reliefClinical trial · people · 2024
- BPC-157: 14 of 16 reported knee pain relief in a chart reviewObservational study · people · 2021
- BPC-157 closed duodenocolic fistulas in ratsAnimal study · rats · 2024
- BPC-157 restored cut muscle-tendon junctions in ratsAnimal study · rats · 2021
- BPC-157 countered succinylcholine hyperkalemia and arrhythmias in ratsAnimal study · rats · 2016
All 6 studies on BPC-157
- BPC-157 sped tendon cell outgrowth and migration in rat cellsCell study · rat Achilles tendon fibroblasts · 2011

Healing & recovery
TB-500
- Thymosin beta-4 sped skin wound healing in diabetic and aged miceAnimal study · mice · 2003
Healing & recovery
GHK-Cu
- GHK-Cu gel: 98.5% median closure of diabetic plantar ulcers vs 60.8%Randomized trial · people · 1994
- GHK-Cu eased lung inflammation and fibrosis in mice with silicosisAnimal study · mice · 2024
- GHK-Cu liposomes sped scald wound healing in miceAnimal study · mice · 2017
- GHK-Cu plus hyaluronic acid raised collagen IV in human fibroblastsCell study · human dermal fibroblasts · 2023
- GHK-Cu raised osteoblastic cell attachment in rat and human cellsCell study · rat calvaria cells, human trabecular osteoblastic cells and human marrow stromal cells · 1995
All 6 studies on GHK-Cu
- GHK-Cu boosted growth of chick embryo cartilage cells in cultureCell study · chick embryo chondrocytes · 1995
Healing & recovery
KPV
- KPV in drinking water reduced colitis in 2 mouse modelsAnimal study · mice · 2008
- KPV reduced white blood cell buildup in mice with peritonitisAnimal study · mice · 2003
Healing & recovery
AOD-9604
- AOD-9604 knee injections lowered cartilage damage in rabbitsAnimal study · rabbits · 2015
- AOD-9604 lowered body weight and body fat in obese mice over 14 daysAnimal study · mice · 2001
- AOD-9604 cut weight gain by over 50% in obese Zucker ratsAnimal study · obese Zucker rats · 2000
- AOD-9604 reduced weight gain and fat tissue mass in obese miceAnimal study · mice · 1994
Healing & recovery
Thymosin Alpha-1
- Thymosin Alpha-1 vs interferon in hepatitis B: better at follow-upMeta-analysis · people · 2008
- Thymosin alpha-1 lowered infections after colorectal cancer surgeryRandomized trial · people · 2024
- Thymosin Alpha-1 combo: 30.0% pCR before gastric cancer surgeryClinical trial · people · 2026
Healing & recovery
Thymosin Beta-4
- Thymosin beta-4: no overall infarct area cut in 96 STEMI patientsRandomized trial · people · 2025
- Thymosin beta-4 in pregnant mice: longer newborns, more mature organsAnimal study · mice · 2021
- Thymosin beta-4 raised survival in mice with a coronavirus infectionAnimal study · mice · 2021
- Thymosin beta-4: more liver fibrosis in mice bred to make extra TB4Animal study · mice · 2017
- Thymosin Beta-4 sped full thickness skin wound healing in ratsAnimal study · rats · 1999
All 7 studies on Thymosin Beta-4
- Thymosin beta-4 rescued AD-linked defects in human brain organoidsCell study · human brain organoids · 2025
- Thymosin beta-4 cut prion-driven leak in human brain endothelial cellsCell study · hCMEC/D3 human cerebral endothelial cells · 2020
Healing & recovery
LL-37
- LL-37 cream: bigger granulation gains in diabetic foot ulcersRandomized trial · people · 2023
- LL-37: no healing gain over placebo for venous leg ulcers overallRandomized trial · people · 2021
- LL-37 drove IL-1β and IL-18 release from human and murine macrophagesCell study · human and murine macrophages · 2013
- LL-37 raised TLR9 and interferon output in human skin cellsCell study · normal human keratinocytes · 2012
Healing & recovery
Larazotide
- Larazotide: eased GI symptoms in celiac patients on gluten challengeMeta-analysis · people · 2022
- Larazotide: no gut permeability rise after gluten in celiac patientsRandomized trial · people · 2007
Healing & recovery
VIP
- VIP (aviptadil): discharge at 7.8 vs 10 days in COVID-19Randomized trial · people · 2025
- VIP fragment VIP10-28 boosted, not blocked, skin vessel wideningClinical trial · people · 2005
- VIP: peak flow rose 26 l/min in severe asthma, less than salbutamolClinical trial · people · 1986
- VIP: tear levels rose after laser eye surgery, peaking at 1 weekObservational study · people · 2023
Healing & recovery
ARA-290
- ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg armRandomized trial · people · 2017
- ARA-290 eased neuropathic symptoms in sarcoidosis nerve fiber lossRandomized trial · people · 2013
- ARA-290 improved small fiber neuropathy symptoms in sarcoidosisRandomized trial · people · 2012
- ARA-290 eased nerve-injury pain for up to 20 weeks in ratsAnimal study · rats · 2014
Healing & recovery
Ac-SDKP
- Ac-SDKP: blood levels fell after kidney transplant in 14 patientsClinical trial · people · 2014
- Ac-SDKP taken by mouth eased kidney scarring in diabetic miceAnimal study · mice · 2016
Growth hormone
Ipamorelin
- Ipamorelin reduced cisplatin weight loss by about 24% in ferretsAnimal study · ferrets · 2024
- Ipamorelin sped gastric emptying after abdominal surgery in ratsAnimal study · rats · 2012
- Ipamorelin sped first bowel movement after gut surgery in ratsAnimal study · rats · 2009
- Ipamorelin for 21 days raised pituitary secretion granules in ratsAnimal study · rats · 2002
- Ipamorelin offset glucocorticoid-linked bone formation drop in ratsAnimal study · rats · 2001
All 9 studies on ipamorelin
- Ipamorelin raised bone mineral content in female rats over 12 weeksAnimal study · rats · 2000
- Ipamorelin: new derivative matched its GH potency in swineAnimal study · rats, swine and dogs · 1998
- Ipamorelin: about 20% nasal bioavailability in ratsAnimal study · rats · 1998
- Ipamorelin released GH without raising ACTH or cortisol in swineAnimal study · rats and swine · 1998
Growth hormone
CJC-1295 with DAC
- CJC-1295 with DAC: one shot raised GH 2- to 10-fold in healthy adultsRandomized trial · people · 2006
- CJC-1295 with DAC changed serum protein patterns in healthy menClinical trial · people · 2009
- CJC-1295 with DAC: trough GH up 7.5-fold, pulses kept in healthy menClinical trial · people · 2006
- CJC-1295 with DAC daily normalized growth in GHRH knockout miceAnimal study · mice · 2006
- CJC-1295 with DAC: 4-fold larger GH response than hGRF(1-29) in ratsAnimal study · rats · 2005
Growth hormone
Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
All 12 studies on tesamorelin
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeksRandomized trial · people · 2010
- Tesamorelin: 10.9% less visceral fat at 6 months in HIV patientsRandomized trial · people · 2010
- Tesamorelin: visceral fat down 18% over 52 weeks in HIV patientsRandomized trial · people · 2008
- Tesamorelin: 15.2% drop in visceral fat at 26 weeks in HIVRandomized trial · people · 2007
- Tesamorelin drug levels unaffected by age, size, race or HIV statusClinical trial · people · 2015
- Tesamorelin: model accurately predicted GH and IGF-1 over 14 daysClinical trial · people · 2015
Growth hormone
GHRP-2
- GHRP-2: 35.9% more food eaten at a buffet meal in healthy menClinical trial · people · 2005
- GHRP-2: 30-day infusion raised GH and IGF-I in older adultsClinical trial · people · 2004
- GHRP-2: stronger GH release than GHRH in 6 healthy young adultsClinical trial · people · 1997
- GHRP-2: chronic dosing made GH response to GHRH combo synergisticClinical trial · people · 1996
Growth hormone
GHRP-6
- GHRP-6 raised night GH, ACTH, cortisol and stage 2 sleep in menRandomized trial · people · 1995
- GHRP-6: weaker growth hormone release in thyrotoxicosis vs controlsClinical trial · people · 2007
- GHRP-6 + GHRH: high blood sugar cut GH response in type 2 diabetesClinical trial · people · 2004
Growth hormone
Hexarelin
- Hexarelin: GH response fell over 16 weeks, recovered after a breakClinical trial · people · 1998
- Hexarelin protected rat hearts from ischemia-reperfusion damageAnimal study · rats · 1999
- Hexarelin kept its growth hormone effect over 60 days in old ratsAnimal study · rats · 1997
Growth hormone
MK-677
- MK-677 raised IGF-1 but not most function after hip fractureRandomized trial · people · 2011
- MK-677: fat-free mass rose 1.1 kg vs -0.5 kg on placebo at 1 yearRandomized trial · people · 2008
- MK-677 reversed diet-driven nitrogen loss in 8 healthy adultsRandomized trial · people · 1998
- MK-677: about 50% more stage IV sleep in young adults on 25 mgClinical trial · people · 1997
Growth hormone
Fragment 176-191
- Fragment 176-191 aided doxorubicin against MCF-7 breast cancer cellsCell study · human MCF-7 breast cancer cells · 2022
Growth hormone
IGF-1 LR3
- IGF-1 LR3 lowered blood sugar longer than native IGF-I in pigsAnimal study · pigs and marmoset monkeys · 1997
- IGF-1 LR3 raised organ weights but not growth in guinea pigsAnimal study · guinea pigs · 1995
- IGF-1 LR3: several times as potent as IGF-I for gut growth in ratsAnimal study · rats · 1992
- IGF-1 LR3: about 2.5-fold more potent than IGF-I in catabolic ratsAnimal study · rats · 1992
Growth hormone
PEG-MGF
- PEG-MGF: heart function preserved after heart attack in miceAnimal study · mice · 2013
- PEG-MGF (MGF): no rise in mouse or human muscle cell proliferationCell study · C2C12 cells, primary human skeletal muscle myoblasts, primary mouse skeletal muscle stem cells and cardiac myocytes · 2014
- PEG-MGF extended division of human muscle cells from young donorsCell study · human muscle cells · 2011
Growth hormone
Follistatin-344
- Follistatin-344 gene therapy: walk gains in some Becker patientsClinical trial · people · 2015
- Follistatin-344: CSCR eye disorder in 11 bodybuilders after injectionObservational study · people · 2020
Metabolic & GLP-1
Semaglutide
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetesRandomized trial · people · 2025
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeksRandomized trial · people · 2025
- Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UPRandomized trial · people · 2025
All 12 studies on semaglutide
- Semaglutide: 24% lower risk of major kidney events in FLOWRandomized trial · people · 2024
- Semaglutide pill: 15.1% weight loss at 68 weeks in OASIS 1Randomized trial · people · 2023
- Semaglutide: 6.5% vs 8.0% had a major heart event in SELECTRandomized trial · people · 2023
- Semaglutide: 35% lower lunch energy intake vs placebo at 20 weeksRandomized trial · people · 2021
- Semaglutide: 14.9% weight loss at 68 weeks in STEP 1Randomized trial · people · 2021
- Semaglutide STEP 4: -7.9% weight vs +6.9% after switch to placeboRandomized trial · people · 2021
- Semaglutide: 6.6% vs 8.9% heart or stroke events in SUSTAIN-6Randomized trial · people · 2016
Metabolic & GLP-1
Semaglutide (oral)
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide (oral): heart risk not higher than placebo in PIONEER 6Randomized trial · people · 2019
Metabolic & GLP-1
Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
All 12 studies on tirzepatide
- Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CNRandomized trial · people · 2024
- Tirzepatide: AHI fell 25.3 and 29.3 events per hour in SURMOUNT-OSARandomized trial · people · 2024
- Tirzepatide: 62% MASH resolution in 15 mg arm vs 10% on placeboRandomized trial · people · 2024
- Tirzepatide 15 mg: 14.7% weight loss at 72 weeks in SURMOUNT-2Randomized trial · people · 2023
- Tirzepatide: HbA1c fell 2.1% vs 1.1% with insulin lispro in SURPASS-6Randomized trial · people · 2023
- Tirzepatide: up to 20.9% weight loss at 72 weeks in SURMOUNT-1Randomized trial · people · 2022
- Tirzepatide: HbA1c fell up to 2.07% at 40 weeks in SURPASS-1Randomized trial · people · 2021
Metabolic & GLP-1
Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
All 12 studies on retatrutide
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeksRandomized trial · people · 2022
- Retatrutide lowered ANGPTL3/8 in step with triglycerides and LDL-CClinical trial · people · 2025
- Retatrutide cut body weight by 31% in obese mice with MASHAnimal study · mice and hamsters · 2026
- Retatrutide: 24.1% weight loss in MC4R-deficient mice over 21 daysAnimal study · mice · 2026
- Retatrutide: 14-fold smaller pancreatic tumors in miceAnimal study · mice · 2025
- Retatrutide eased diet-induced steatohepatitis in female miceAnimal study · mice · 2025
Metabolic & GLP-1
Liraglutide
- Liraglutide: 6.4% weight loss vs 15.8% on semaglutide in STEP 8Randomized trial · people · 2022
- Liraglutide plus exercise: 9.5 kg more loss than placebo at 1 yearRandomized trial · people · 2021
- Liraglutide: 13.0% vs 14.9% major cardiovascular events in LEADERRandomized trial · people · 2016
- Liraglutide: 8.4 kg lost vs 2.8 kg on placebo at 56 weeksRandomized trial · people · 2015
Metabolic & GLP-1
Dulaglutide
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeksRandomized trial · people · 2022
- Dulaglutide lowered major cardiovascular events (HR 0.88) in REWINDRandomized trial · people · 2019
- Dulaglutide cut HbA1c and weight less than semaglutide in SUSTAIN 7Randomized trial · people · 2018
Metabolic & GLP-1
Orforglipron
- Orforglipron: heart events no worse than insulin in ACHIEVE-4Randomized trial · people · 2026
- Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2Randomized trial · people · 2026
- Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1Randomized trial · people · 2025
- Orforglipron: food lowered drug exposure by 17.6% to 23.7%Clinical trial · people · 2024
Metabolic & GLP-1
Survodutide
- Survodutide: 12.2% weight loss and less liver fat at 48 weeksRandomized trial · people · 2026
- Survodutide: up to 14.9% weight loss at 46 weeks in phase 2 trialRandomized trial · people · 2024
Metabolic & GLP-1
Mazdutide
- Mazdutide: 16.65% average weight loss at 60 weeks in GLORY-2Randomized trial · people · 2026
- Mazdutide beat dulaglutide on HbA1c and weight at 28 weeksRandomized trial · people · 2026
- Mazdutide: HbA1c fell 2.15% at 24 weeks in type 2 diabetesRandomized trial · people · 2026
- Mazdutide: 14.01% weight loss at 48 weeks in GLORY-1 (6 mg arm)Randomized trial · people · 2025
Metabolic & GLP-1
Pemvidutide
- Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trialRandomized trial · people · 2026
- Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLDRandomized trial · people · 2025
- Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeksRandomized trial · people · 2025
- Pemvidutide cut body weight about 25% in mice with NASHAnimal study · mice · 2022
Metabolic & GLP-1
Cagrilintide
- Cagrilintide with semaglutide: 17.1% weight loss at 2.4 mg, week 20Randomized trial · people · 2021
Metabolic & GLP-1
CagriSema
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
Metabolic & GLP-1
5-Amino-1MQ
- 5-Amino-1MQ slowed bladder tumor growth in miceAnimal study · mice · 2024
- 5-Amino-1MQ plus low-fat diet gave obese mice a distinct microbiomeAnimal study · mice · 2022
- 5-Amino-1MQ slowed growth of HeLa cervical cancer cells in the labCell study · HeLa cervical cancer cells · 2021
Metabolic & GLP-1
SLU-PP-332
- SLU-PP-332 cut fat mass and improved insulin sensitivity in obese miceAnimal study · mice · 2024
- SLU-PP-332 improved ejection fraction and survival in miceAnimal study · mice · 2024
- SLU-PP-332 increased exercise endurance in miceAnimal study · mice · 2023
- SLU-PP-332 reversed age-related kidney changes in old miceAnimal study · mice · 2023
Metabolic & GLP-1
Oxytocin
- Oxytocin: no gain over placebo on autism social measures at 24 weeksRandomized trial · people · 2021
- Oxytocin nasal spray cut calories eaten at a breakfast test in menRandomized trial · people · 2015
- Oxytocin given in the nose raised trust in a controlled human trialClinical trial · people · 2005
- Oxytocin in mice: 10ng/h raised anxiety; 1ng/h averted stress anxietyAnimal study · mice · 2014
Longevity
MOTS-c
- MOTS-c rose after 16 weeks of exercise in non-Hispanic White survivorsRandomized trial · people · 2021
- MOTS-c reduced islet cell senescence and glucose intolerance in miceAnimal study · mice · 2025
- MOTS-c eased lung ischemia-reperfusion injury and deaths in ratsAnimal study · rats · 2025
- MOTS-c improved heart mitochondrial respiration in diabetic ratsAnimal study · rats · 2025
- MOTS-c prevented muscle atrophy, raised muscle glucose uptake in miceAnimal study · mice · 2024
All 9 studies on MOTS-c
- MOTS-c raised testosterone, LH and FSH in obese and non-obese ratsAnimal study · rats · 2024
- MOTS-c improved heart small-vessel barrier under endotoxin in miceAnimal study · mice · 2024
- MOTS-c eased high blood sugar in mice with gestational diabetesAnimal study · mice · 2022
- MOTS-c lowered insulin, raised glucagon in pancreatic cell linesCell study · INS-1E and αTC-1 pancreatic cell lines · 2024
Longevity
NAD+
- NAD+: NR and NMN, not nicotinamide, raised blood NAD+ in 14 daysRandomized trial · people · 2026
- NMN raised serum nicotinamide over 12 weeks in middle-aged adultsRandomized trial · people · 2023
- NMN raised muscle insulin sensitivity in women with prediabetesRandomized trial · people · 2021
- NAD+ rose with nicotinamide riboside in a 6-week crossover trialRandomized trial · people · 2018
Longevity
Glutathione
- Glutathione: oral doses raised body glutathione stores over 6 monthsRandomized trial · people · 2015
- Glutathione: oral dose did not raise plasma levels in 7 adultsClinical trial · people · 1992
- Glutathione IV: plasma level rose to 823 µmol/l, half-life 14.1 minClinical trial · people · 1991
Longevity
Epitalon
- Epitalon: night melatonin rose in elderly with low pineal functionRandomized trial · people · 2004
- Epitalon: positive clinical effect in 90% of retinal lesion casesClinical trial · people · 2002
- Epitalon restored wound healing in high-glucose human retinal cellsCell study · human retinal pigment epithelial cells (ARPE-19) · 2025
- Epitalon lowered ROS and apoptosis in aging mouse oocytes in vitroCell study · mouse oocytes · 2022
Longevity
Humanin
- Humanin: blood levels rise with age, highest in centenariansObservational study · people · 2019
- Humanin inhibited IGFBP-3 cell death in human glioblastoma cellsCell study · human glioblastoma A172 cells and mouse cortical neurons · 2003
Longevity
FOXO4-DRI
- FOXO4-DRI improved sperm quality in naturally aged miceAnimal study · mice · 2024
- FOXO4-DRI eased age-related testosterone shortfall in aged miceAnimal study · mice · 2020
- FOXO4-DRI raised cell death in lab-grown keloid fibroblastsCell study · human keloid fibroblasts · 2025
- FOXO4-DRI cleared senescent cells from expanded human chondrocytesCell study · human chondrocytes · 2021
Longevity
SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
All 12 studies on SS-31
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- SS-31 did not significantly cut infarct size in EMBRACE STEMIRandomized trial · people · 2016
- SS-31 (elamipretide) lowered blood HtrA2 after STEMI heart attackClinical trial · people · 2019
- SS-31: 79.7 m better walk test vs untreated in Barth syndromeObservational study · people · 2022
- SS-31 aided functional recovery after spinal cord injury in miceAnimal study · mice · 2023
- SS-31 partly undid age-related muscle phosphorylation in old miceAnimal study · mice · 2022
- SS-31 eased LPS-induced learning and memory problems in miceAnimal study · mice · 2019
Longevity
Pinealon
- Pinealon improved learning in offspring of rats fed extra methionineAnimal study · rats · 2012
- Pinealon lowered free radicals and cell death in PC12 and brain cellsCell study · cerebellar granule cells, neutrophils and PC12 cells · 2011
Longevity
Vesugen
- Vesugen (KED) prevented dendritic spine loss in Alzheimer's miceAnimal study · mice · 2021
Longevity
Klotho
- Klotho: higher genetic levels tied to lower atrial fibrillation riskMeta-analysis · people · 2022
- Klotho: one low dose enhanced memory in aged nonhuman primatesAnimal study · aged nonhuman primates · 2023
- Klotho: higher levels improved learning and memory in miceAnimal study · mice · 2014
Longevity
NMN
- NMN: no significant benefit on blood sugar or lipids in pooled trialsMeta-analysis · people · 2024
- NMN: raised blood NAD over 60 days in 80 middle-aged adultsRandomized trial · people · 2023
- NMN supplements raised blood NAD+ levels in healthy older menRandomized trial · people · 2022
- NMN: aerobic gains at 600 and 1200 mg/day in amateur runnersRandomized trial · people · 2021
Longevity
DSIP
- DSIP: longer, less interrupted sleep in 6 people with chronic insomniaClinical trial · people · 1981
Cognitive
Dihexa
- Dihexa plus stem cells improved rat motor function after nerve repairAnimal study · rats · 2021
- Dihexa showed antidementia activity in scopolamine and aged rat modelsAnimal study · rats · 2013
Cognitive
Selank
- Selank and GABA changed expression of 45 rat brain genes at 1 hourAnimal study · rats · 2016
Cognitive
Semax
- Semax shifted BDNF and NGF gene activity in rat brain within 1 hourAnimal study · rats · 2007
- Semax raised hippocampal BDNF levels up to 1.4-fold in ratsAnimal study · rats · 2006
- Semax raised striatal 5-HIAA to 180% in rodentsAnimal study · rodents · 2005
Cognitive
NSI-189
- NSI-189 80 mg beat placebo in moderate, not severe, depressionRandomized trial · people · 2020
- NSI-189 eased nerve damage and memory problems in diabetic ratsAnimal study · rats · 2022
- NSI-189 protected nerves and memory in diabetic miceAnimal study · mice · 2019
- NSI-189 eased motor and neurological deficits after stroke in ratsAnimal study · rats · 2017
Cognitive
P21
- P21: lowered tau in the brain and spinal fluid of aged ratsAnimal study · rats · 2015
- P21 reduced tau buildup and cognitive deficits in Alzheimer's miceAnimal study · mice · 2014
Cognitive
Cerebrolysin
- Cerebrolysin: better NIHSS scores after stroke across nine trialsMeta-analysis · people · 2018
- Cerebrolysin beat placebo on global change in Alzheimer's at 6 monthsMeta-analysis · people · 2015
- Cerebrolysin: better arm function at day 90 after stroke in CARSRandomized trial · people · 2016
- Cerebrolysin: no overall benefit in acute ischemic stroke at 90 daysRandomized trial · people · 2012
Sexual health
PT-141
- PT-141: side-effect dropouts far higher than placebo in re-analysisMeta-analysis · people · 2021
- PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeksRandomized trial · people · 2016
- PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety dataSystematic review · people · 2022
Sexual health
Kisspeptin-10
- Kisspeptin-10: daily 8 h infusions kept LH raised for 12 days in menRandomized trial · people · 2026
- Kisspeptin-10 raised osteocalcin by up to 20.3% in healthy menRandomized trial · people · 2022
Sexual health
Enclomiphene
- Enclomiphene or clomiphene raised testosterone vs placebo in menMeta-analysis · people · 2025
- Enclomiphene raised testosterone, kept sperm counts normal vs gelRandomized trial · people · 2016
- Enclomiphene raised testosterone like gel and also raised sperm countsRandomized trial · people · 2013
- Enclomiphene 25 mg: testosterone 604 ng/dL by Day 42, similar to gelRandomized trial · people · 2013
Sexual health
Melanotan II
- Melanotan II: erections in 17 of 20 men with erectile dysfunctionClinical trial · people · 2000
- Melanotan II: erections in 8 of 10 men with psychogenic EDClinical trial · people · 1998
- Melanotan II: darker skin in 2 of 3 men in a small phase I trialClinical trial · people · 1996
- Melanotan II: melanoma diagnosed in a 20-year-old woman after useObservational study · people · 2014
Sexual health
Melanotan I
- Melanotan I: more pain-free sun time in protoporphyria trialsRandomized trial · people · 2015
- Melanotan I plus UV-B: 48.64% vitiligo repigmentation at day 168Randomized trial · people · 2015
- Melanotan I: well tolerated in 6 acute stroke patientsClinical trial · people · 2023
By kind
Meta-analysis
- Thymosin Alpha-1 vs interferon in hepatitis B: better at follow-upMeta-analysis · people · 2008
- Larazotide: eased GI symptoms in celiac patients on gluten challengeMeta-analysis · people · 2022
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Klotho: higher genetic levels tied to lower atrial fibrillation riskMeta-analysis · people · 2022
- NMN: no significant benefit on blood sugar or lipids in pooled trialsMeta-analysis · people · 2024
- Cerebrolysin: better NIHSS scores after stroke across nine trialsMeta-analysis · people · 2018
- Cerebrolysin beat placebo on global change in Alzheimer's at 6 monthsMeta-analysis · people · 2015
- PT-141: side-effect dropouts far higher than placebo in re-analysisMeta-analysis · people · 2021
- Enclomiphene or clomiphene raised testosterone vs placebo in menMeta-analysis · people · 2025
By kind
Randomized trial
- GHK-Cu gel: 98.5% median closure of diabetic plantar ulcers vs 60.8%Randomized trial · people · 1994
- Thymosin alpha-1 lowered infections after colorectal cancer surgeryRandomized trial · people · 2024
- Thymosin beta-4: no overall infarct area cut in 96 STEMI patientsRandomized trial · people · 2025
- LL-37 cream: bigger granulation gains in diabetic foot ulcersRandomized trial · people · 2023
- LL-37: no healing gain over placebo for venous leg ulcers overallRandomized trial · people · 2021
- Larazotide: no gut permeability rise after gluten in celiac patientsRandomized trial · people · 2007
- VIP (aviptadil): discharge at 7.8 vs 10 days in COVID-19Randomized trial · people · 2025
- ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg armRandomized trial · people · 2017
- ARA-290 eased neuropathic symptoms in sarcoidosis nerve fiber lossRandomized trial · people · 2013
- ARA-290 improved small fiber neuropathy symptoms in sarcoidosisRandomized trial · people · 2012
- CJC-1295 with DAC: one shot raised GH 2- to 10-fold in healthy adultsRandomized trial · people · 2006
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeksRandomized trial · people · 2010
- Tesamorelin: 10.9% less visceral fat at 6 months in HIV patientsRandomized trial · people · 2010
- Tesamorelin: visceral fat down 18% over 52 weeks in HIV patientsRandomized trial · people · 2008
- Tesamorelin: 15.2% drop in visceral fat at 26 weeks in HIVRandomized trial · people · 2007
- GHRP-6 raised night GH, ACTH, cortisol and stage 2 sleep in menRandomized trial · people · 1995
- MK-677 raised IGF-1 but not most function after hip fractureRandomized trial · people · 2011
- MK-677: fat-free mass rose 1.1 kg vs -0.5 kg on placebo at 1 yearRandomized trial · people · 2008
- MK-677 reversed diet-driven nitrogen loss in 8 healthy adultsRandomized trial · people · 1998
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetesRandomized trial · people · 2025
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeksRandomized trial · people · 2025
- Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UPRandomized trial · people · 2025
- Semaglutide: 24% lower risk of major kidney events in FLOWRandomized trial · people · 2024
- Semaglutide pill: 15.1% weight loss at 68 weeks in OASIS 1Randomized trial · people · 2023
- Semaglutide: 6.5% vs 8.0% had a major heart event in SELECTRandomized trial · people · 2023
- Semaglutide: 35% lower lunch energy intake vs placebo at 20 weeksRandomized trial · people · 2021
- Semaglutide: 14.9% weight loss at 68 weeks in STEP 1Randomized trial · people · 2021
- Semaglutide STEP 4: -7.9% weight vs +6.9% after switch to placeboRandomized trial · people · 2021
- Semaglutide: 6.6% vs 8.9% heart or stroke events in SUSTAIN-6Randomized trial · people · 2016
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide (oral): heart risk not higher than placebo in PIONEER 6Randomized trial · people · 2019
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
- Tirzepatide: up to 17.5% weight loss at 52 weeks in SURMOUNT-CNRandomized trial · people · 2024
- Tirzepatide: AHI fell 25.3 and 29.3 events per hour in SURMOUNT-OSARandomized trial · people · 2024
- Tirzepatide: 62% MASH resolution in 15 mg arm vs 10% on placeboRandomized trial · people · 2024
- Tirzepatide 15 mg: 14.7% weight loss at 72 weeks in SURMOUNT-2Randomized trial · people · 2023
- Tirzepatide: HbA1c fell 2.1% vs 1.1% with insulin lispro in SURPASS-6Randomized trial · people · 2023
- Tirzepatide: up to 20.9% weight loss at 72 weeks in SURMOUNT-1Randomized trial · people · 2022
- Tirzepatide: HbA1c fell up to 2.07% at 40 weeks in SURPASS-1Randomized trial · people · 2021
- Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trialsRandomized trial · people · 2026
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeksRandomized trial · people · 2022
- Liraglutide: 6.4% weight loss vs 15.8% on semaglutide in STEP 8Randomized trial · people · 2022
- Liraglutide plus exercise: 9.5 kg more loss than placebo at 1 yearRandomized trial · people · 2021
- Liraglutide: 13.0% vs 14.9% major cardiovascular events in LEADERRandomized trial · people · 2016
- Liraglutide: 8.4 kg lost vs 2.8 kg on placebo at 56 weeksRandomized trial · people · 2015
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeksRandomized trial · people · 2022
- Dulaglutide lowered major cardiovascular events (HR 0.88) in REWINDRandomized trial · people · 2019
- Dulaglutide cut HbA1c and weight less than semaglutide in SUSTAIN 7Randomized trial · people · 2018
- Orforglipron: heart events no worse than insulin in ACHIEVE-4Randomized trial · people · 2026
- Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2Randomized trial · people · 2026
- Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1Randomized trial · people · 2025
- Survodutide: 12.2% weight loss and less liver fat at 48 weeksRandomized trial · people · 2026
- Survodutide: up to 14.9% weight loss at 46 weeks in phase 2 trialRandomized trial · people · 2024
- Mazdutide: 16.65% average weight loss at 60 weeks in GLORY-2Randomized trial · people · 2026
- Mazdutide beat dulaglutide on HbA1c and weight at 28 weeksRandomized trial · people · 2026
- Mazdutide: HbA1c fell 2.15% at 24 weeks in type 2 diabetesRandomized trial · people · 2026
- Mazdutide: 14.01% weight loss at 48 weeks in GLORY-1 (6 mg arm)Randomized trial · people · 2025
- Pemvidutide: liver fat down 54.7% at 48 weeks in IMPACT MASH trialRandomized trial · people · 2026
- Pemvidutide: up to 76.4% liver fat reduction at 24 weeks in MASLDRandomized trial · people · 2025
- Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeksRandomized trial · people · 2025
- Cagrilintide with semaglutide: 17.1% weight loss at 2.4 mg, week 20Randomized trial · people · 2021
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Oxytocin: no gain over placebo on autism social measures at 24 weeksRandomized trial · people · 2021
- Oxytocin nasal spray cut calories eaten at a breakfast test in menRandomized trial · people · 2015
- MOTS-c rose after 16 weeks of exercise in non-Hispanic White survivorsRandomized trial · people · 2021
- NAD+: NR and NMN, not nicotinamide, raised blood NAD+ in 14 daysRandomized trial · people · 2026
- NMN raised serum nicotinamide over 12 weeks in middle-aged adultsRandomized trial · people · 2023
- NMN raised muscle insulin sensitivity in women with prediabetesRandomized trial · people · 2021
- NAD+ rose with nicotinamide riboside in a 6-week crossover trialRandomized trial · people · 2018
- Glutathione: oral doses raised body glutathione stores over 6 monthsRandomized trial · people · 2015
- Epitalon: night melatonin rose in elderly with low pineal functionRandomized trial · people · 2004
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- SS-31 did not significantly cut infarct size in EMBRACE STEMIRandomized trial · people · 2016
- NMN: raised blood NAD over 60 days in 80 middle-aged adultsRandomized trial · people · 2023
- NMN supplements raised blood NAD+ levels in healthy older menRandomized trial · people · 2022
- NMN: aerobic gains at 600 and 1200 mg/day in amateur runnersRandomized trial · people · 2021
- NSI-189 80 mg beat placebo in moderate, not severe, depressionRandomized trial · people · 2020
- Cerebrolysin: better arm function at day 90 after stroke in CARSRandomized trial · people · 2016
- Cerebrolysin: no overall benefit in acute ischemic stroke at 90 daysRandomized trial · people · 2012
- PT-141: +0.7 vs +0.2 satisfying sexual events a month at 12 weeksRandomized trial · people · 2016
- Kisspeptin-10: daily 8 h infusions kept LH raised for 12 days in menRandomized trial · people · 2026
- Kisspeptin-10 raised osteocalcin by up to 20.3% in healthy menRandomized trial · people · 2022
- Enclomiphene raised testosterone, kept sperm counts normal vs gelRandomized trial · people · 2016
- Enclomiphene raised testosterone like gel and also raised sperm countsRandomized trial · people · 2013
- Enclomiphene 25 mg: testosterone 604 ng/dL by Day 42, similar to gelRandomized trial · people · 2013
- Melanotan I: more pain-free sun time in protoporphyria trialsRandomized trial · people · 2015
- Melanotan I plus UV-B: 48.64% vitiligo repigmentation at day 168Randomized trial · people · 2015
By kind
Clinical trial
- BPC-157: 10 of 12 women reported full interstitial cystitis reliefClinical trial · people · 2024
- Thymosin Alpha-1 combo: 30.0% pCR before gastric cancer surgeryClinical trial · people · 2026
- VIP fragment VIP10-28 boosted, not blocked, skin vessel wideningClinical trial · people · 2005
- VIP: peak flow rose 26 l/min in severe asthma, less than salbutamolClinical trial · people · 1986
- Ac-SDKP: blood levels fell after kidney transplant in 14 patientsClinical trial · people · 2014
- CJC-1295 with DAC changed serum protein patterns in healthy menClinical trial · people · 2009
- CJC-1295 with DAC: trough GH up 7.5-fold, pulses kept in healthy menClinical trial · people · 2006
- Tesamorelin drug levels unaffected by age, size, race or HIV statusClinical trial · people · 2015
- Tesamorelin: model accurately predicted GH and IGF-1 over 14 daysClinical trial · people · 2015
- GHRP-2: 35.9% more food eaten at a buffet meal in healthy menClinical trial · people · 2005
- GHRP-2: 30-day infusion raised GH and IGF-I in older adultsClinical trial · people · 2004
- GHRP-2: stronger GH release than GHRH in 6 healthy young adultsClinical trial · people · 1997
- GHRP-2: chronic dosing made GH response to GHRH combo synergisticClinical trial · people · 1996
- GHRP-6: weaker growth hormone release in thyrotoxicosis vs controlsClinical trial · people · 2007
- GHRP-6 + GHRH: high blood sugar cut GH response in type 2 diabetesClinical trial · people · 2004
- Hexarelin: GH response fell over 16 weeks, recovered after a breakClinical trial · people · 1998
- MK-677: about 50% more stage IV sleep in young adults on 25 mgClinical trial · people · 1997
- Follistatin-344 gene therapy: walk gains in some Becker patientsClinical trial · people · 2015
- Retatrutide lowered ANGPTL3/8 in step with triglycerides and LDL-CClinical trial · people · 2025
- Orforglipron: food lowered drug exposure by 17.6% to 23.7%Clinical trial · people · 2024
- Oxytocin given in the nose raised trust in a controlled human trialClinical trial · people · 2005
- Glutathione: oral dose did not raise plasma levels in 7 adultsClinical trial · people · 1992
- Glutathione IV: plasma level rose to 823 µmol/l, half-life 14.1 minClinical trial · people · 1991
- Epitalon: positive clinical effect in 90% of retinal lesion casesClinical trial · people · 2002
- SS-31 (elamipretide) lowered blood HtrA2 after STEMI heart attackClinical trial · people · 2019
- DSIP: longer, less interrupted sleep in 6 people with chronic insomniaClinical trial · people · 1981
- Melanotan II: erections in 17 of 20 men with erectile dysfunctionClinical trial · people · 2000
- Melanotan II: erections in 8 of 10 men with psychogenic EDClinical trial · people · 1998
- Melanotan II: darker skin in 2 of 3 men in a small phase I trialClinical trial · people · 1996
- Melanotan I: well tolerated in 6 acute stroke patientsClinical trial · people · 2023
By kind
Observational study
- BPC-157: 14 of 16 reported knee pain relief in a chart reviewObservational study · people · 2021
- VIP: tear levels rose after laser eye surgery, peaking at 1 weekObservational study · people · 2023
- Follistatin-344: CSCR eye disorder in 11 bodybuilders after injectionObservational study · people · 2020
- Humanin: blood levels rise with age, highest in centenariansObservational study · people · 2019
- SS-31: 79.7 m better walk test vs untreated in Barth syndromeObservational study · people · 2022
- Melanotan II: melanoma diagnosed in a 20-year-old woman after useObservational study · people · 2014
By kind
Systematic review
- PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety dataSystematic review · people · 2022
By kind
Animal study
- BPC-157 closed duodenocolic fistulas in ratsAnimal study · rats · 2024
- BPC-157 restored cut muscle-tendon junctions in ratsAnimal study · rats · 2021
- BPC-157 countered succinylcholine hyperkalemia and arrhythmias in ratsAnimal study · rats · 2016
- Thymosin beta-4 sped skin wound healing in diabetic and aged miceAnimal study · mice · 2003
- GHK-Cu eased lung inflammation and fibrosis in mice with silicosisAnimal study · mice · 2024
- GHK-Cu liposomes sped scald wound healing in miceAnimal study · mice · 2017
- KPV in drinking water reduced colitis in 2 mouse modelsAnimal study · mice · 2008
- KPV reduced white blood cell buildup in mice with peritonitisAnimal study · mice · 2003
- AOD-9604 knee injections lowered cartilage damage in rabbitsAnimal study · rabbits · 2015
- AOD-9604 lowered body weight and body fat in obese mice over 14 daysAnimal study · mice · 2001
- AOD-9604 cut weight gain by over 50% in obese Zucker ratsAnimal study · obese Zucker rats · 2000
- AOD-9604 reduced weight gain and fat tissue mass in obese miceAnimal study · mice · 1994
- Thymosin beta-4 in pregnant mice: longer newborns, more mature organsAnimal study · mice · 2021
- Thymosin beta-4 raised survival in mice with a coronavirus infectionAnimal study · mice · 2021
- Thymosin beta-4: more liver fibrosis in mice bred to make extra TB4Animal study · mice · 2017
- Thymosin Beta-4 sped full thickness skin wound healing in ratsAnimal study · rats · 1999
- ARA-290 eased nerve-injury pain for up to 20 weeks in ratsAnimal study · rats · 2014
- Ac-SDKP taken by mouth eased kidney scarring in diabetic miceAnimal study · mice · 2016
- Ipamorelin reduced cisplatin weight loss by about 24% in ferretsAnimal study · ferrets · 2024
- Ipamorelin sped gastric emptying after abdominal surgery in ratsAnimal study · rats · 2012
- Ipamorelin sped first bowel movement after gut surgery in ratsAnimal study · rats · 2009
- Ipamorelin for 21 days raised pituitary secretion granules in ratsAnimal study · rats · 2002
- Ipamorelin offset glucocorticoid-linked bone formation drop in ratsAnimal study · rats · 2001
- Ipamorelin raised bone mineral content in female rats over 12 weeksAnimal study · rats · 2000
- Ipamorelin: new derivative matched its GH potency in swineAnimal study · rats, swine and dogs · 1998
- Ipamorelin: about 20% nasal bioavailability in ratsAnimal study · rats · 1998
- Ipamorelin released GH without raising ACTH or cortisol in swineAnimal study · rats and swine · 1998
- CJC-1295 with DAC daily normalized growth in GHRH knockout miceAnimal study · mice · 2006
- CJC-1295 with DAC: 4-fold larger GH response than hGRF(1-29) in ratsAnimal study · rats · 2005
- Hexarelin protected rat hearts from ischemia-reperfusion damageAnimal study · rats · 1999
- Hexarelin kept its growth hormone effect over 60 days in old ratsAnimal study · rats · 1997
- IGF-1 LR3 lowered blood sugar longer than native IGF-I in pigsAnimal study · pigs and marmoset monkeys · 1997
- IGF-1 LR3 raised organ weights but not growth in guinea pigsAnimal study · guinea pigs · 1995
- IGF-1 LR3: several times as potent as IGF-I for gut growth in ratsAnimal study · rats · 1992
- IGF-1 LR3: about 2.5-fold more potent than IGF-I in catabolic ratsAnimal study · rats · 1992
- PEG-MGF: heart function preserved after heart attack in miceAnimal study · mice · 2013
- Retatrutide cut body weight by 31% in obese mice with MASHAnimal study · mice and hamsters · 2026
- Retatrutide: 24.1% weight loss in MC4R-deficient mice over 21 daysAnimal study · mice · 2026
- Retatrutide: 14-fold smaller pancreatic tumors in miceAnimal study · mice · 2025
- Retatrutide eased diet-induced steatohepatitis in female miceAnimal study · mice · 2025
- Pemvidutide cut body weight about 25% in mice with NASHAnimal study · mice · 2022
- 5-Amino-1MQ slowed bladder tumor growth in miceAnimal study · mice · 2024
- 5-Amino-1MQ plus low-fat diet gave obese mice a distinct microbiomeAnimal study · mice · 2022
- SLU-PP-332 cut fat mass and improved insulin sensitivity in obese miceAnimal study · mice · 2024
- SLU-PP-332 improved ejection fraction and survival in miceAnimal study · mice · 2024
- SLU-PP-332 increased exercise endurance in miceAnimal study · mice · 2023
- SLU-PP-332 reversed age-related kidney changes in old miceAnimal study · mice · 2023
- Oxytocin in mice: 10ng/h raised anxiety; 1ng/h averted stress anxietyAnimal study · mice · 2014
- MOTS-c reduced islet cell senescence and glucose intolerance in miceAnimal study · mice · 2025
- MOTS-c eased lung ischemia-reperfusion injury and deaths in ratsAnimal study · rats · 2025
- MOTS-c improved heart mitochondrial respiration in diabetic ratsAnimal study · rats · 2025
- MOTS-c prevented muscle atrophy, raised muscle glucose uptake in miceAnimal study · mice · 2024
- MOTS-c raised testosterone, LH and FSH in obese and non-obese ratsAnimal study · rats · 2024
- MOTS-c improved heart small-vessel barrier under endotoxin in miceAnimal study · mice · 2024
- MOTS-c eased high blood sugar in mice with gestational diabetesAnimal study · mice · 2022
- FOXO4-DRI improved sperm quality in naturally aged miceAnimal study · mice · 2024
- FOXO4-DRI eased age-related testosterone shortfall in aged miceAnimal study · mice · 2020
- SS-31 aided functional recovery after spinal cord injury in miceAnimal study · mice · 2023
- SS-31 partly undid age-related muscle phosphorylation in old miceAnimal study · mice · 2022
- SS-31 eased LPS-induced learning and memory problems in miceAnimal study · mice · 2019
- Pinealon improved learning in offspring of rats fed extra methionineAnimal study · rats · 2012
- Vesugen (KED) prevented dendritic spine loss in Alzheimer's miceAnimal study · mice · 2021
- Klotho: one low dose enhanced memory in aged nonhuman primatesAnimal study · aged nonhuman primates · 2023
- Klotho: higher levels improved learning and memory in miceAnimal study · mice · 2014
- Dihexa plus stem cells improved rat motor function after nerve repairAnimal study · rats · 2021
- Dihexa showed antidementia activity in scopolamine and aged rat modelsAnimal study · rats · 2013
- Selank and GABA changed expression of 45 rat brain genes at 1 hourAnimal study · rats · 2016
- Semax shifted BDNF and NGF gene activity in rat brain within 1 hourAnimal study · rats · 2007
- Semax raised hippocampal BDNF levels up to 1.4-fold in ratsAnimal study · rats · 2006
- Semax raised striatal 5-HIAA to 180% in rodentsAnimal study · rodents · 2005
- NSI-189 eased nerve damage and memory problems in diabetic ratsAnimal study · rats · 2022
- NSI-189 protected nerves and memory in diabetic miceAnimal study · mice · 2019
- NSI-189 eased motor and neurological deficits after stroke in ratsAnimal study · rats · 2017
- P21: lowered tau in the brain and spinal fluid of aged ratsAnimal study · rats · 2015
- P21 reduced tau buildup and cognitive deficits in Alzheimer's miceAnimal study · mice · 2014
By kind
Cell study
- BPC-157 sped tendon cell outgrowth and migration in rat cellsCell study · rat Achilles tendon fibroblasts · 2011
- GHK-Cu plus hyaluronic acid raised collagen IV in human fibroblastsCell study · human dermal fibroblasts · 2023
- GHK-Cu raised osteoblastic cell attachment in rat and human cellsCell study · rat calvaria cells, human trabecular osteoblastic cells and human marrow stromal cells · 1995
- GHK-Cu boosted growth of chick embryo cartilage cells in cultureCell study · chick embryo chondrocytes · 1995
- Thymosin beta-4 rescued AD-linked defects in human brain organoidsCell study · human brain organoids · 2025
- Thymosin beta-4 cut prion-driven leak in human brain endothelial cellsCell study · hCMEC/D3 human cerebral endothelial cells · 2020
- LL-37 drove IL-1β and IL-18 release from human and murine macrophagesCell study · human and murine macrophages · 2013
- LL-37 raised TLR9 and interferon output in human skin cellsCell study · normal human keratinocytes · 2012
- Fragment 176-191 aided doxorubicin against MCF-7 breast cancer cellsCell study · human MCF-7 breast cancer cells · 2022
- PEG-MGF (MGF): no rise in mouse or human muscle cell proliferationCell study · C2C12 cells, primary human skeletal muscle myoblasts, primary mouse skeletal muscle stem cells and cardiac myocytes · 2014
- PEG-MGF extended division of human muscle cells from young donorsCell study · human muscle cells · 2011
- 5-Amino-1MQ slowed growth of HeLa cervical cancer cells in the labCell study · HeLa cervical cancer cells · 2021
- MOTS-c lowered insulin, raised glucagon in pancreatic cell linesCell study · INS-1E and αTC-1 pancreatic cell lines · 2024
- Epitalon restored wound healing in high-glucose human retinal cellsCell study · human retinal pigment epithelial cells (ARPE-19) · 2025
- Epitalon lowered ROS and apoptosis in aging mouse oocytes in vitroCell study · mouse oocytes · 2022
- Humanin inhibited IGFBP-3 cell death in human glioblastoma cellsCell study · human glioblastoma A172 cells and mouse cortical neurons · 2003
- FOXO4-DRI raised cell death in lab-grown keloid fibroblastsCell study · human keloid fibroblasts · 2025
- FOXO4-DRI cleared senescent cells from expanded human chondrocytesCell study · human chondrocytes · 2021
- Pinealon lowered free radicals and cell death in PC12 and brain cellsCell study · cerebellar granule cells, neutrophils and PC12 cells · 2011